Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1646 1674
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17383316 | METHOD FOR THE EXPRESSION OF AN ANTIBODY-MULTIMER-FUSION | Non-Final OA | Genentech, Inc. |
| 17642515 | IMMUNOACTIVE MICROPARTICLES AND USES THEREOF | Final Rejection | The Regents of the University of California |
| 17638519 | IMPLANTABLE SCAFFOLDS AND USES THEREOF FOR IMMUNOTHERAPY AND OTHER USES | Final Rejection | The Regents of the University of California |
| 18644528 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | Final Rejection | Genzyme Corporation |
| 17189970 | MOBILIZED PERIPHERAL BLOOD AS A SOURCE OF MODIFIED IMMUNE CELLS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17800345 | ANTI- MUC1-SEA ANTIBODIES | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 17142072 | METHODS AND COMPOSITIONS FOR MODULATING MYELOPEROXIDASE (MPO) EXPRESSION | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 17633255 | METHOD OF TREATING KELOIDS | Final Rejection | Icahn School of Medicine at Mount Sinai |
| 18327255 | HUMAN ANTIBODIES TO TN ANTIGEN | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17624541 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Final Rejection | ZYMEWORKS BC INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy